INTRODUCTION
============

Aquaporins (AQP) belong to a family of water or solute channels that are widely expressed in various epithelia and endothelia as well as in other cell types such as epidermis, adipocytes, and skeletal muscle ([@b16-molce-39-4-292]; [@b18-molce-39-4-292]). In mammals, there are 13 different AQPs, defined as AQP0 to AQP12 ([@b26-molce-39-4-292]). AQP0, 1, 2, 4, 5, and 8 function mainly as water-selective transporters. AQP3, 7, 9, and 10 are aquaglyceroporins that transport both water and glycerol ([@b28-molce-39-4-292]). AQPs play important role in regulating physiological functions such as neuroexcitatory processes in central nerve system ([@b27-molce-39-4-292]), epidermal proliferation in skin keratinocytes ([@b9-molce-39-4-292]), urinary concentration in kidney ([@b25-molce-39-4-292]), and transepithelial fluid secretion in exocrine glands ([@b24-molce-39-4-292]). AQPs are also involved in cell migration and vessel formation. Inhibition of AQP dependent angiogenesis impairs tumor growth in a mouse model of melanoma ([@b20-molce-39-4-292]).

AQP1 is specifically and strongly expressed in most microvasculature endothelial cells ([@b2-molce-39-4-292]; [@b12-molce-39-4-292]). The increase of AQP1 expression accounts for in myocardial edema during cardiopulmonary bypass ([@b7-molce-39-4-292]). AQP1 knockdown resulted in high permeability in pulmonary microvasculature ([@b19-molce-39-4-292]). It has been shown that ischemia, hypoxia, and cardioplegia could reduce cardiac AQP1 level ([@b4-molce-39-4-292]), where AQP1 is mostly located in microvasculature and t-tubules of myocardial cells ([@b12-molce-39-4-292]; [@b29-molce-39-4-292]). Although the distribution and roles of AQP1 in endothelial cells have been established, the regulation of endothelial expression of AQP1 has not been fully understood.

The transcription factor myocyte enhancer factor 2 (MEF2) family proteins bind to a consensus sequence CTA(A/T)4TAG in the promoter region of target genes ([@b15-molce-39-4-292]). Mef2c is expressed in endothelial cells (ECs) both *in vivo* ([@b13-molce-39-4-292]) and *in vitro* ([@b10-molce-39-4-292]; [@b14-molce-39-4-292]) and play a particularly important role in angiogenesis during vascular development. Whole body knockout of Mef2c leads to early embryonic death resulted from cardiac defects while targeted deletion of Mef2c in mice leads to severe vascular defects ([@b13-molce-39-4-292]). Transcriptome analyses using Mef2-deficient cells identified several downstream genes including c-fos and Arc that function to control synaptic remodeling ([@b6-molce-39-4-292]). In the hematopoietic compartment, Mef2c regulates leukemic cell migration and invasionby targeting chemokine ligands ([@b21-molce-39-4-292]), chemokine receptors and matrix metalloproteinase genes. It is still uncertain which componentsare targeted by Mef2c during angiogenesis.

This study aimed to elucidate the regulatory mechanism for AQP1 transcription by Mef2c. The interaction between Mef2c and its binding site was analyzed by DNA affinity precipitation and chromatin immunoprecipitation, cell migration with wound healing assay, and vasculogenesis by tube formation assays. Our data showed that Mef2c cooperated with Sp1 to activate human AQP1 transcription by binding to its proximal promoter in human umbilical cord vein endothelial cells (HUVEC), Over-expression of Mef2c, Sp1, or Mef2c/Sp1 increased HUVEC migration and tube-forming ability, which can be abolished AQP-1 knockdown. The data indicated that Aqp1 is a direct target of Mef2c in endothelial cells and angiogenic and vasculogenic activities of Mef2c.

MATERIAL AND METHODS
====================

Cell Culture, transient transfection, and luciferase assays
-----------------------------------------------------------

Human umbilical cord vein endothelial cells (HUVEC) (ATCC, USA) were maintained in DMEM/high-glucose medium supplemented with 20% FBS, penicillin-streptomycin (100 U/ml and 100 mg/ml, respectively) (Invitrogen, China), heparin (90 mg/ml, Sigma, USA), and endothelial cell growth factor (20 mg/ml, Fisher Scientific, USA) at 37°C in a humidified atmosphere with 5% CO~2~. One day before transfection, HUVEC cells were seeded into 12-well plates to allow 50--70% confluence on the day of transfection. Reporter constructs and expression vectors were transfected using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. 50 ng/well vector TK-renilla (Promega, USA) was transfected as internal control. Total DNA was kept at 1.0 mg/well. Corresponding empty vectors were used as standard in different treatment groups. Luciferase activity was measured 48 h later using dual-luciferase assay kit (Promega) and read on a microtiter plate luminometer (Dynex, USA). All experiments were performed in triplicates. Results were shown as relative luciferase activity and expressed as mean ± S.E from at least three independent experiments.

Luciferase reporter vectors and expression vectors
--------------------------------------------------

The promoter region of human AQP1 gene was amplified from human genomic DNA with primers listed in [Table 1](#t1-molce-39-4-292){ref-type="table"}, digested with *Bg*lII and *Xin*dIII, and cloned into pGL3-vector which was digested with the same enzymes to generate 1.6 kb, 500 bp, 260 bp, 210 bp, 100 bp, and 30 bp constructs. The mutant reporter gene constructs were generated based on pGL3-hAQP1-210 with indicated primers ([Table 1](#t1-molce-39-4-292){ref-type="table"}) using Quick-kit (Stratagene). All constructs were confirmed by DNA sequencing. Flag-Mef2c was kindly provided by Dr. Skerjanc (University of Ottawa). Sp1 vector was described elsewhere ([@b29-molce-39-4-292]).

Quantitative real-time PCR
--------------------------

Total RNA from mouse heart or HUVECs was extracted using RNeasy Mini Kit (Qiagen, China) according to manufacturer's instructions. The first strand cDNA was synthesized using a reverse transcription kit from Tiangen Bio (China) according to manufacturer's protocol.

Quantitative real-time PCR was performed with a qPCR kit from TransGen (China) on a Eppendorf Realplex with specified primers ([Table. 1](#t1-molce-39-4-292){ref-type="table"}). The reaction program was consisted of 95°C for 3 min followed by 40 cycles of 95°C 30 s, 55°C 20 s, and 72°C 20 s. GAPDH or β-actin gene were served as internal control and the relative mRNA levels were calculated by 2^−ΔΔCt^.

Western blot
------------

The total protein from HUVECs was resolved by SDS-polyacrylamide gel electrophoresis before transferred onto a PVDF membrane. The membrane was blocked with 5% non-fat milk and incubated with primary antibody against AQP1 (USA), Mef2c (Abcam, USA), or Sp1 (Abcam,) followed by incubation with horseradish peroxidase conjugated secondary antibody. An enhanced chemiluminescence (ECL) (Sangon, China) was used to visualize the protein bands. The protein bands were then analyzed by Image J (National Institutes of Health) software.

DNA affinity precipitation assays (DAPA)
----------------------------------------

The extraction of nuclear protein from HUVECs and DNA affinity precipitation assay were performed as described previously ([@b29-molce-39-4-292]). The sequences for the oligonucleotides used in DAPA assay were listed in [Table 1](#t1-molce-39-4-292){ref-type="table"} with mutated nucleotides in lowercase.

Chromatin immunoprecipitation (CHIP)
------------------------------------

The atria and ventricles of E13 mouse embryos were collected in cold PBS. Mouse heart tissue and HUVEC cells CHIP were performed using an EpiQuik Tissue Chromatin Immunoprecipitation (ChIP) Kit (Epigentek, USA) and am EpiXplore™ ChIP Assay Kit (Clontech, USA) according to the manufacturers' protocols, respectively. Antibodies used for CHIP were anti-Mef2c (sc-13266 X, Santa Cruz, USA) or normal goat IgG (control). Chipped DNA samples were subjected to quantitative PCR. Fold enrichment indicated the ratio of CHIPed DNA to the IgG control, normalized for input DNA. Primer sequences were listed in [Table 1](#t1-molce-39-4-292){ref-type="table"}.

Cell motility assay
-------------------

HUVEC cells were seeded in 6-well plates 24 h before being transfected with indicated plasmids and scratched with a pipette tip 24 h after transfection. The gap was measured under a microscope immediately after scratching and after 24 h of culture. The assay was performed three times with 3 replicates each. The relative migration rate was calculated as: relative migration rate =(di-dt)~exp~/(di-dt)~ctrl~ × 100, where di was the initial gap width, dt was the gap width after 24 h of culture, exp was individual treatments, and ctrl was the control cell without any treatment.

Vascular tube formation assay
-----------------------------

HUVEC cells were transfected as described 24 h before the assay. On the day of the assay, 50 μl of BD Matrigel was added into 96-well plates and incubated at 37°C for 30 min. Tranfected HUVEC cells were trypsinized and adjusted to a concentration of 5 × 10^4^ cells/ml with complete culture medium, and 100 μl of cells were seeded into each well. The cells were photographed and tubes were counted in 5 random fields (100×) 48 h later. The assay was performed in three independent experiments with 5 replicates each. The relative tube formation activity = N~exp~/N~Ctrl~, where N~exp~ was the number of vascular tubes of each treatment group and N~Ctrl~ was the number of vascular tubes of the control group.

RNA interference against AQP1
-----------------------------

Two pairs of RNA oligonucleotides targeting different regions of AQP1 ([@b23-molce-39-4-292]) and a control pair were custom-synthesized by Sangon (China). Double stranded siRNA was transfected into NIH 3T3 cells using Lipofectamine 2000 (Invitrogen, China) according to the manufacturer's instructions. The protein and mRNA level were measured 48 h later by western blot with specified antibodies and quantitative real-time PCR using ABI Prism 7300 (Applied Biosystems, USA), respectively.

Statistic analysis
------------------

The data was expressed as mean ± S.E. The differences between groups were analyzed by Student's *t*-test. *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Mef2c increased human AQP1 promoter activity
--------------------------------------------

To identify the cis-element important for the transcriptional activation of human AQP1 gene, a serial 5′ truncation of hAQP1 promoter was inserted into pGL3-vector. The luciferase activity was analyzed 2 days after transfection into HUVEC cells. The promoter activity of human AQP1 was almost abrogated in the −30 construct which contained an intact TATA-box whereas all other constructs had consistently high promoter activities ([Fig. 1A](#f1-molce-39-4-292){ref-type="fig"}). A Mef2 binding site was identified assessing hAQP1 proximal promoter sequence, which was conserved among human, mouse, and rat ([Fig. 1B](#f1-molce-39-4-292){ref-type="fig"}). When cotransfecting with Mef2c expression vector, the luciferase activity of hAQP1 (−1000 kb) was 2.4-fold higher than cotransfected with control empty vector ([Fig. 1C](#f1-molce-39-4-292){ref-type="fig"}).

Mef2c cooperated with Sp1 in activating human AQP1 transcription
----------------------------------------------------------------

To confirm the role of Mef2 binding site in human AQP1 transcription, the Mef2 site and the adjacent Sp1 binding site were mutated individually or simultaneously followed by luciferase assays. Mutating the Mef2, Sp1, or both Mef2 and Sp1 sites caused 50%, 70%, and 90% reduction of AQP1 promoter activity ([Table 1](#t1-molce-39-4-292){ref-type="table"}, pAQP1_mSp1, pAQP1_mMef2, pAQP1_mSp1/Mef2 and [Fig. 2A](#f2-molce-39-4-292){ref-type="fig"}). On the other hand, cotransfection of Mef2c, Sp1, or Mef2c/Sp1 increased human AQP1 promoter activity 2.4, 5.0, and 8.3 folds, respectively ([Fig. 2B](#f2-molce-39-4-292){ref-type="fig"}). The AQP1 mRNA levels in HUVEC cells transfected with Mef2c, Sp1, and Mef2c/Sp1 expression vectors were 50%, 60%, and 90% higher than that of control cells ([Fig. 2C](#f2-molce-39-4-292){ref-type="fig"}). The AQP1 protein levels HUVEC cells were also significantly increased by over expression of Mef2c and/ or Sp1 ([Figs. 2D and 2E](#f2-molce-39-4-292){ref-type="fig"}).

Mef2c bound to human AQP1 proximal promoter
-------------------------------------------

Using biotin labeled polynucleotides corresponding to the human AQP1 promoter region containing Sp1 and Mef2c binding sites, the Mef2c and Sp1 proteins were precipitated from HUVEC nuclear proteins by wild type polynucleotide but not by the polynucleotide with mutated Mef2c and Sp1-binding sites ([Figs. 3A and 3B](#f3-molce-39-4-292){ref-type="fig"}). Mef2c specific antibodies strongly enriched the chromatin fragments containing Mef2c binding sites but not other regions in the AQP1 promoter without a Mef2c binding site in either HUVEC cells ([Fig. 3C](#f3-molce-39-4-292){ref-type="fig"}) or mouse hearts ([Fig. 3D](#f3-molce-39-4-292){ref-type="fig"}).

Mef2c regulated HUVEC migration through AQP1
--------------------------------------------

Knockdown AQP1 expression reduced the migrating ability of HUVEC cells by 85% ([Fig. 4A](#f4-molce-39-4-292){ref-type="fig"}). On the other hand, overexpression of Mef2c, Sp1, or Mef2c/Sp1 increased HUVEC migration by 84%, 92%, and 154%, respectively. Knockdown AQP1 completely abrogated the increased motility of HUVEC cells resulted from Mef2c/Sp1 over-expression ([Fig. 4B](#f4-molce-39-4-292){ref-type="fig"}).

Mef2c increased vascular tube formation of HUVEC cells
------------------------------------------------------

Over-expression of Mef2c, Sp1, and Mef2c/Sp1 significantly increased in vitro tube-forming ability of HUVEC cells by 2 to 4 folds, and such increase was abolished by knockdown AQP1 expression ([Fig. 5A](#f5-molce-39-4-292){ref-type="fig"}). Knockdown AQP1 expression alone in HUVEC cells reduced tube number by more than 50% ([Fig. 5B](#f5-molce-39-4-292){ref-type="fig"}).

DISCUSSION
==========

Mef2c activates human AQP1 transcription in endothelial cells with cooperation of Sp1 through the specific binding sites in the proximal promoter region. Disrupting either MEF2 or adjacent Sp1 binding site or both significantly reduce AQP1 promoter activities. Mef2c controlls HUVEC cells migration and tube forming through regulation of AQP1 expression.

AQP1 promotes angiogenesis by increasing the motility of endothelial cells ([@b20-molce-39-4-292]; [@b23-molce-39-4-292]). AQP1-null endothelial cells migrates slower more than 50% compared with wild-type cells, which is recovered by ectopic AQP1 expression ([@b20-molce-39-4-292]). The lack of AQP1 impaires tumor angiogenesis and tumor growth due to increased necrosis ([@b23-molce-39-4-292]), and causes abnormal microvascular structure and reduces vascular density in breast cancer ([@b8-molce-39-4-292]). The present data showed that knockdown AQP1 level reduced both migration and vascular tube formation of endothelial cells in basal and Mef2c-overexpression background.

Mef2c has been shown to be critical for vasculogenesis and angiogenesis during vascular development and mediate vascular endothelial growth factor ([@b14-molce-39-4-292]). Mef2c deficiency causes severe abnormalities of vascular development including failed maturation of extra embryonic vasculature, severe malformation of embryonic vasculature, and malformed endocardium ([@b3-molce-39-4-292]). Mef2 protein is significantly reduced in myotonic dystrophy type 1 heart accompanied by a change of expression profile of both microRNAs and mRNAs, which could be restored by exogenous Mef2c ([@b5-molce-39-4-292]). Deletion of Mef2c from endothelial cells represses vessel loss in oxygen-induced retinopathy and significantly increased revascularization ([@b11-molce-39-4-292]).

The activity of Mef2c during vascular development is modulated by homeodomain interacting protein kinase through direct interaction in a transforming growth factor (TGF)-β-TAK1-dependent manner ([@b30-molce-39-4-292]). Sry-related HMG box gene Sox18 and Mef2c interacts with each other in endothelial cells to direct the transcription of genes involved in vascular development ([@b22-molce-39-4-292]). Mef2c also interacts with SOX10 to potentiate its own transcription in melanocyte development ([@b10-molce-39-4-292]). In the present study, Mef2c functionally interacted with Sp1 to activate the transcription of AQP1 gene, which partially conferred the angiogenic activity of Mef2c.

All together, these data expand understanding of the physiological role of AQP1 except for its water transport function. The regulation of AQP1 by Mef2c in endothelial cells during vasculogenesis and angiogenesis are summarized in [Fig. 6](#f6-molce-39-4-292){ref-type="fig"}. It has been demonstrated that interactions of aquaporin and cytoskeletal elements or ion transporters at the tip of a lamellipodium drive the influx of water across the cell membrane ([@b20-molce-39-4-292]). Solute and water influx then increases local hydrostatic pressure to create space for actin polymerization, which might contribute to aquaporin-dependent cell human endothelial migration. Earlier study by [@b1-molce-39-4-292] show that up-regulation of AQP1 by hypoxia may result in increased membrane water permeability and account for edema associated in tumor mircroenvrioment. HIF1-α and other transcription factors are identified to regulate AQP1 promotor activity. Our findings suggest that different transcription factors may involve in regulation of AQP1 in normal cells and in diseases and thepossibility to consider tissue specific AQP1 targeting forvarious pathophysiological conditions.
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![Identification of transcription factors important for human Aqp1 expression. (A) Human AQP1 promoter 5′ deletion luciferase report constructs were transfected into HUVEC cells and luciferase activities were measured 48 h later. (B) The alignment of the proximal region of human, mouse, and rat AQP1 promoters. The grey shaded region indicated Sp1-binding (GC-rich) site, the boxed area indicated the Mef2c-binding site which overlapped with TATA box. (C) Human AQP1 reporter gene (pAQP1-210) was co-transfected with either pcDNA3.1 or Mef2c expression vector into HUVEC cells followed by luciferase activity assay 48 h later.](molce-39-4-292f1){#f1-molce-39-4-292}

![Mef2c activates the transcription of human Aqp1 gene. (A). Wild type pAQP1-100 or Mef2c and/ or Sp1-binding site mutant constructs were transfected into HUVEC cells and luciferase activities were measured 2 days later. (B) pAQP1-100 construct was cotransfected with Mef2c, Sp1, or both and luciferase activities were measured 48 h post-transfection. HUVEC cells were transfected with empty vector, Mef2c, Sp1, or both, (C) AQP1 mRNA and (D, E) protein levels were analyzed 48 h later.](molce-39-4-292f2){#f2-molce-39-4-292}

![Mef2c and Sp1 bind to the Mef2 and Sp1 sites in human AQP1 promoter. (A, B) 5′ biotin labeled nucleotides corresponding to the Mef2 and Sp1 sites or their mutants of human AQP1 promoter were incubated with HUVEC cell nuclear extracts and precipitated with TetralinkTMavidin resin. The DNA-protein complexes were resolved in SDS-PAGE gel and immunoblotted with antibodies against Mef2c and Sp1. HUVEC cells (C) and embryonic mouse heart tissues (D) were chromatin immunoprecipitated with antibody against Mef2c or normal IgG and the resultant DNA samples were analyzed by qPCR with primers encompassing regions with or without Mef2 binding site.](molce-39-4-292f3){#f3-molce-39-4-292}

![Mef2c promotes HUVEC migration through AQP1. (A) HUVEC cells transfected with control empty vectors, siAQP1, Mef2c, Sp1, Mef2c/Sp1, or Mef2c/Sp1/siAQP1 were scratched with a blue tip 24 h after transfection. The gap distance was measured after scratch and 24 h later. (B) The relative migration distance of cells with different treatment was calculated against untreated cells.](molce-39-4-292f4){#f4-molce-39-4-292}

![Mef2c promotes HUVEC cell tube formation through AQP1. (A) HUVEC cells transfected with control empty vectors, siAQP1, Mef2c, Sp1, Mef2c/Sp1, or Mef2c/Sp1/siAQP1 were seeded on Matrigel and incubated for 24 h before being photographed and analysis. (B) The relative tube-forming activity of cells with different treatment was calculated against untreated cells.](molce-39-4-292f5){#f5-molce-39-4-292}

![The regulation of AQP1 by Mef2c in endothelial cells during vasculogenesis and angiogenesis](molce-39-4-292f6){#f6-molce-39-4-292}

###### 

The sequences of nucleotide primers used in the study.

  --------------------------------------------------------------------------------------------------------------------------------------
                     Gene                                                      Oligonucleotide sequence
  ------------------ --------------------------------------------------------- ---------------------------------------------------------
  Promoter study     pAQP1-1.6k_F                                              GGA AGATCTCCACTCATCCTTGCCCTGCCCC

  pAQP1-500_F        GGAAGATCTGTGCCCCCATCCACAGAGCCCT                           

  pAQP1-260_F        GGAAGATCTCCGCCCACCCCACCCACTCC                             

  pAQP1-210_F        GGAAGATCTCCTCCTGCCTGCCTCCTTGGG                            

  pAQP1-100_F        GGAAGATCTACAGCCGTGTCTGCATCCATCCAG                         

  pAQP1_R            CCCAAGCTTAGGGGGCTTGGCCTGAGACCG                            

  pAQP1-30_F         GATCTTATAAATAGGCCCAGCCCAGGCTGTGGCTCAGA                    

  pAQP1-30_R         AGCTTCTGAGCCACAGCCTGGGCTGGGCCTATTTATAA                    

  pAQP1_mSp1         CTTTGTGCTCCCTATATATCCCGGCCCTAT\                           
                     ATAGGGCCGGGATATATAGGGAGCACAAAG                            

  pAQP1_mMef2c       CCGGCCATATAAATATATCCAGCCCAG\                              
                     CTGGGCTGGATATATTTATATGGCCGG                               

  pAQP1_mSp1/Mef2c   CTTTGTGCTCCCTATATATCCCGGCCATATAAATATATCCAGCCCAG\          
                     CTGGGCTGGATATATTTATATGGCCGGGATATATAGGGAGCACAAAG           

  q-PCR              mmAQP1                                                    GGGCAGTAATATCACTGTCTT\
                                                                               GTGGGTCCCTCACTTTCA

  hAQP1              TCTCAGGCATCACCTCCTCC\                                     
                     CGAGTTCACACCATCAGCCA                                      

  mmMef2c            CACCTACATAACATGCCGCC\                                     
                     AGGCTTTGAGTAGAAGGCAGG                                     

  hMef2c             TGGAGAAGCACTTCAACGCT\                                     
                     CCTGATGAAGGAAGACCCGA                                      

  mmβ-actin          GGTCATCACTATTGGCAACG\                                     
                     ACGGATGTCAACGTCACACT                                      

  hGAPDH             GCACCGTCAAGGCTGAGAAC\                                     
                     TGGTGAAGACGCCAGTGGA                                       

  siRNA              siAQP1-1S                                                 GGGUGGAGAUGAAGCCCAAdTdT

  siAQP1-1A          UUGGGCUUCAUCUCCACCCdTdT                                   

  siAQP1-2S          UGGAGAUGAAGCCCAAAUAdTdT                                   

  siAQP1-2A          UAUUUGGGCUUCAUCUCCAdTdT                                   

  siControl-S        UGGAGAAGGCCAACUAGGGdTdT                                   

  siControl-A        CCCUAGUUGGCCUUCUCCAdTdT                                   

  DAPA assay         bio-AQP1_F                                                biotin-TGTGCTCCCCCC[G]{.ul}CCCCCCGGCCCTATAAATAGGCCCAGCC

  AQP1_R             GGCTGGGCCTATTTATAGGGCCGGGGGGCGGGGGGAGCACA                 

  bio-mAQP1_F        biotin-TGTGCTCCaCaC[G]{.ul}aCCaCCGaCCaTATAAATAaGaCCAGCC   

  mAQP1_R            GGCTGGtCtTATTTATAtGGtCGGtGGtCGtGtGGAGCACA                 

  CHIP-qPCR          hCHIP1_F                                                  TGTCTCTGCCACTCT

  hCHIP1_R           GACTTGAGGAAAGAAGCA                                        

  hCHIP2_F           AGGTCTGTGTGGTGT                                           

  hCHIP2_R           TCAATTCCCTCTGAGA                                          

  mmCHIP1_F          TGGAAGATGGAATTCGT                                         

  mmCHIP1_R          CTCTACCCAGTTCACT                                          

  mmCHIP2_F          GGCCTTCCTCCCTTT                                           

  mmCHIP2_R          ATGCCTGGTGCTCAA                                           
  --------------------------------------------------------------------------------------------------------------------------------------

h, human; m, mutant; mm, mouse
